Thank you for your interest
Listen to the Podcast below
CHI interviews Dr. Xavier Jacq, Head of Biology at MISSION Therapeutics regarding drugging deubiquitinase enzymes (DUBs), a rapidly emerging target class within the Ubiquitin Proteasome System (UPS). Discussion topics and questions include:
- Tell us a little about MISSION and your current programs.
- Why are DUBs emerging as viable therapeutic targets?
- What are drug discovery challenges in this space? What about inhibitor discovery, how challenging is this?
- What might be challenges surrounding translating these compounds into the clinic?
- What are some novel tools and technologies being developed to overcome some of these challenges?
- You are giving a lecture at the 13th Annual Discovery on Target Conference, during the Targeting the Ubiquitin Proteasome System meeting. What do you hope to convey
to attendees during your lecture this fall?
- How have you seen this field evolve over the past few years, and where do you see it going in the future?